Edward Calvin Kendall

Edward Calvin Kendall passed away on May 4, 1972, in Princeton, New Jersey, at the age of 86. His death marked the end of a life characterized by significant scientific achievements, particularly in the field of endocrinology. Kendall's contributions to the understanding and treatment of hormonal diseases continue to benefit medical research and patient care.

Edward Calvin Kendall retired from the Mayo Clinic in 1961 after a distinguished career that greatly advanced the understanding of hormones and their therapeutic applications. His retirement marked the end of an era of groundbreaking research, but his legacy continued through the countless lives improved by his discoveries and the ongoing research in steroid chemistry.

In 1956, Edward Calvin Kendall's research led to the development of synthetic cortisone, which made the treatment of various inflammatory conditions more accessible and affordable. This development represented a major advancement in pharmaceutical manufacturing and hormone therapy, facilitating broader patient access to effective treatments for rheumatoid arthritis and other ailments.

In 1951, Edward Calvin Kendall was elected to the National Academy of Sciences, an institution that recognizes significant achievements in scientific research. This honor highlighted Kendall's contributions to chemistry and medicine, particularly his pioneering work on hormones that have had a lasting impact on how diseases are treated and managed in the field of endocrinology.

Edward Calvin Kendall was awarded the Nobel Prize in Physiology or Medicine on October 23, 1950, sharing it with Philip S. Hench and Tadeus Reichstein. The award recognized their discoveries related to the hormones of the adrenal cortex, with a particular focus on the hormone cortisone and its profound impact on the treatment of inflammatory conditions such as rheumatoid arthritis.

By 1949, Edward Calvin Kendall, along with colleagues, achieved a breakthrough in the development and application of cortisone for the treatment of rheumatoid arthritis. This marked a revolutionary step in therapy for inflammatory diseases, providing significant relief for patients suffering from severe pain and debilitation, altering the course of treatment in rheumatology.

Edward Calvin Kendall became the Chief Chemist at the Mayo Clinic in 1936, a position that allowed him to extend his research on the adrenal cortex hormones. His work at the Mayo Clinic was instrumental in the eventual isolation of the hormone cortisone, which would become pivotal in the treatment of rheumatoid arthritis and other inflammatory diseases, impacting countless lives.

In 1914, Edward Calvin Kendall successfully isolated the hormone thyroxine from the thyroid gland. This discovery was crucial in understanding thyroid function and managing conditions such as hypothyroidism. The identification and synthesis of thyroxine allowed medical professionals to treat thyroid-related illnesses more effectively, marking a significant advancement in endocrinology.

Edward Calvin Kendall earned his PhD in Chemistry from Columbia University in 1910. His early work included research at the Parke, Davis Research Laboratory and the research staff of St. Luke's Hospital in New York City. His education laid the foundation for his future contributions to biochemistry and medicine, particularly in the study of hormones and cortisone.

Edward Calvin Kendall was born on March 8, 1886, in South Norwalk, Connecticut, USA. He went on to become a renowned American chemist, awarded the Nobel Prize for Physiology or Medicine in 1950 for his work on the hormone cortisone. Kendall's research significantly advanced the understanding of the adrenal cortex's functions in the human body, influencing treatments for various diseases.